Literature DB >> 26608083

Application of a Micropatterned Cocultured Hepatocyte System To Predict Preclinical and Human-Specific Drug Metabolism.

T Eric Ballard1, Shuai Wang2, Loretta M Cox2, Mark A Moen2, Stacy Krzyzewski2, Okechukwu Ukairo2, R Scott Obach2.   

Abstract

Laboratory animal models are the industry standard for preclinical risk assessment of drug candidates. Thus, it is important that these species possess profiles of drug metabolites that are similar to those anticipated in human, since metabolites also could be responsible for biologic activities or unanticipated toxicity. Under most circumstances, preclinical species reflect human in vivo metabolites well; however, there have been several notable exceptions, and understanding and predicting these exceptions with an in vitro system would be very useful. Human micropatterned cocultured (MPCC) hepatocytes have been shown to recapitulate human in vivo qualitative metabolic profiles, but the same demonstration has not been performed yet for laboratory animal species. In this study, we investigated several compounds that are known to produce human-unique metabolites through CYP2C9, UGT1A4, aldehyde oxidase (AO), or N-acetyltransferase that were poorly covered or not detected at all in the selected preclinical species. To perform our investigation we used 24-well MPCC hepatocyte plates having three individual human donors and a single donor each of monkey, dog, and rat to study drug metabolism at four time points per species. Through the use of the multispecies MPCC hepatocyte system, the metabolite profiles of the selected compounds in human donors effectively captured the qualitative in vivo metabolite profile with respect to the human metabolite of interest. Human-unique metabolites that were not detected in vivo in certain preclinical species (normally dog and rat) were also not generated in the corresponding species in vitro, confirming that the MPCC hepatocytes can provide an assessment of preclinical species metabolism. From these results, we conclude that multispecies MPCC hepatocyte plates could be used as an effective in vitro tool for preclinical understanding of species metabolism relative to humans and aid in the choice of appropriate preclinical models.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26608083     DOI: 10.1124/dmd.115.066688

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  12 in total

1.  Advances in Engineered Human Liver Platforms for Drug Metabolism Studies.

Authors:  Gregory H Underhill; Salman R Khetani
Journal:  Drug Metab Dispos       Date:  2018-08-22       Impact factor: 3.922

2.  Long-Term Engineered Cultures of Primary Mouse Hepatocytes for Strain and Species Comparison Studies During Drug Development.

Authors:  Brenton R Ware; Grace E Brown; Valerie Y Soldatow; Edward L LeCluyse; Salman R Khetani
Journal:  Gene Expr       Date:  2019-07-24

Review 3.  Microfabrication of liver and heart tissues for drug development.

Authors:  Grace E Brown; Salman R Khetani
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-07-05       Impact factor: 6.237

Review 4.  Considerations for Improving Metabolism Predictions for In Vitro to In Vivo Extrapolation.

Authors:  Marjory Moreau; Pankajini Mallick; Marci Smeltz; Saad Haider; Chantel I Nicolas; Salil N Pendse; Jeremy A Leonard; Matthew W Linakis; Patrick D McMullen; Rebecca A Clewell; Harvey J Clewell; Miyoung Yoon
Journal:  Front Toxicol       Date:  2022-04-29

5.  Modeling Therapeutic Antibody-Small Molecule Drug-Drug Interactions Using a Three-Dimensional Perfusable Human Liver Coculture Platform.

Authors:  Thomas J Long; Patrick A Cosgrove; Robert T Dunn; Donna B Stolz; Hisham Hamadeh; Cynthia Afshari; Helen McBride; Linda G Griffith
Journal:  Drug Metab Dispos       Date:  2016-09-12       Impact factor: 3.922

6.  Controlled Apoptosis of Stromal Cells to Engineer Human Microlivers.

Authors:  Amanda X Chen; Arnav Chhabra; H-H Greco Song; Heather E Fleming; Christopher S Chen; Sangeeta N Bhatia
Journal:  Adv Funct Mater       Date:  2020-06-08       Impact factor: 18.808

7.  Fluid Dynamic Modeling to Support the Development of Flow-Based Hepatocyte Culture Systems for Metabolism Studies.

Authors:  Jenny M Pedersen; Yoo-Sik Shim; Vaibhav Hans; Martin B Phillips; Jeffrey M Macdonald; Glenn Walker; Melvin E Andersen; Harvey J Clewell; Miyoung Yoon
Journal:  Front Bioeng Biotechnol       Date:  2016-09-30

Review 8.  Progress in Prediction and Interpretation of Clinically Relevant Metabolic Drug-Drug Interactions: a Minireview Illustrating Recent Developments and Current Opportunities.

Authors:  Stephen Fowler; Peter N Morcos; Yumi Cleary; Meret Martin-Facklam; Neil Parrott; Michael Gertz; Li Yu
Journal:  Curr Pharmacol Rep       Date:  2017-02-01

Review 9.  Bioengineered Liver Models for Drug Testing and Cell Differentiation Studies.

Authors:  Gregory H Underhill; Salman R Khetani
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2017-12-06

10.  Metabolites of alectinib in human: their identification and pharmacological activity.

Authors:  Mika Sato-Nakai; Kosuke Kawashima; Toshito Nakagawa; Yukako Tachibana; Miyuki Yoshida; Kenji Takanashi; Peter N Morcos; Martin Binder; David J Moore; Li Yu
Journal:  Heliyon       Date:  2017-07-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.